专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2005278498A Method for diagnosing arteriosclerosis and ischemic disease 审中-公开
标题翻译：用于诊断椎弓根病和间质疾病的方法
公开(公告)号：JP2005278498A
公开(公告)日：2005-10-13
申请号：JP2004097464
申请日：2004-03-30
申请人： Yasushi Imai , Ryozo Nagai , 靖今井 , 良三永井
发明人： NAGAI RYOZO , IMAI YASUSHI
IPC分类号： C12N15/09 , C12Q1/68
摘要： PROBLEM TO BE SOLVED: To provide a diagnostic method by which possibility of progress of arteriosclerosis and onset risk of ischemic diseases such as cardiac infarction caused by arteriosclerosis are accurately estimated and further, treatment results to ischemic diseases and prognostic expectation are made possible.
SOLUTION: The method for estimating progress of arteriosclerosis and/onset risk of diseases caused by arteriosclerosis comprises a step for measuring polymorphism of a KLF5 gene by using a biological sample separated from mammals including human and the estimation method comprises a step for determining that progress of arteriosclerosis is rapid and/or onset risk of disease caused by arteriosclerosis is high when the polymorphism is (1) a monobasic polymorphism existing in a 5' adjacent region to KLF5 gene, acting on KLF5 promoter activity and necessary for response to angiotensin II or (2) a monobasic polymorphism existing in exon or intron of KLF5 and influencing on function or gene expression of KLF5.
COPYRIGHT: (C)2006,JPO&NCIPI
摘要翻译：要解决的问题：提供一种诊断方法，通过该方法可以准确地估计动脉硬化进展和缺血性疾病如动脉硬化引起的心肌梗死的发病风险，进一步可以对缺血性疾病和预后期望进行治疗。解决方案：用于估计由动脉硬化引起的疾病的动脉硬化进展和/起始风险的方法包括通过使用从包括人的哺乳动物分离的生物样品来测量KLF5基因的多态性的步骤，并且所述估计方法包括确定当多态性为（1）存在于KLF5基因的5'相邻区域中的单碱性多态性时，动脉硬化的进展是快速的和/或由动脉硬化引起的疾病的发病风险高，作用于KLF5启动子活性并且对于血管紧张素反应是必需的 II或（2）存在于KLF5的外显子或内含子中的单碱性多态性，并影响KLF5的功能或基因表达。版权所有（C）2006，JPO＆NCIPI

2. 发明专利

JP2005239631A Medicine having vascularization-promoting action 有权
标题翻译：具有血管扩张作用的药物
公开(公告)号：JP2005239631A
公开(公告)日：2005-09-08
申请号：JP2004051218
申请日：2004-02-26
申请人： Hiroshi Iwata , Ichiro Manabe , Ryozo Nagai , Research Foundation Itsuu Laboratory , Takayuki Shindo , 洋岩田 , 隆行新藤 , 良三永井 , 一郎眞鍋 , 財団法人乙卯研究所
发明人： NAGAI RYOZO , MANABE ICHIRO , SHINDO TAKAYUKI , IWATA HIROSHI , SHUDO KOICHI , KAGECHIKA HIROYUKI
IPC分类号： C07D243/38 , A61K31/192 , A61K31/196 , A61K31/353 , A61K31/382 , A61K31/403 , A61K31/4184 , A61K31/5513 , A61K45/00 , A61P3/02 , A61P9/00 , A61P9/10 , A61P17/02 , C07D209/58 , C07D235/02 , C07D311/58 , C07D335/06
摘要： PROBLEM TO BE SOLVED: To provide a medicine having a vascularization-promoting action, and useful for preventing and/or treating ischemic diseases, wounds such as bedsore and tissue deficit.
SOLUTION: This medicine having the vascularization-promoting activity contains a retinoid antagonist such as 4-(5H-7,8,9,10-tetrahydro-5,7,7,10,10-pentamethylbenzo[e]naphtho[2,3-b][1,4]diazepin-13-yl) benzoate as an active ingredient, and is useful for preventing and/or treating the ischemic diseases or the wounds.
COPYRIGHT: (C)2005,JPO&NCIPI
摘要翻译：要解决的问题：提供具有血管促进作用的药物，可用于预防和/或治疗缺血性疾病，褥疮和组织缺损等伤口。解决方案：具有促血管活性的这种药物含有类视黄醇拮抗剂如4-（5H-7,8,9,10-四氢-5,7,7,10,10-五甲基苯并[e]萘并[ 2,3-b] [1,4]二氮杂萘-13-基）苯甲酸酯作为活性成分，可用于预防和/或治疗缺血性疾病或伤口。版权所有（C）2005，JPO＆NCIPI

3. 发明专利

JP2006180710A Rna inhibiting expression of klf5 gene 审中-公开
标题翻译： RNA抑制KLF5基因的表达
公开(公告)号：JP2006180710A
公开(公告)日：2006-07-13
申请号：JP2004075115
申请日：2004-03-16
申请人： Kyowa Hakko Kogyo Co Ltd , Ichiro Manabe , Ryozo Nagai , 協和醗酵工業株式会社 , 良三永井 , 一郎眞鍋
发明人： NAGAI RYOZO , MANABE ICHIRO , ISHIHARA ATSUSHI , TOTTORI TSUNEAKI
IPC分类号： C12N15/09 , A61K31/7105 , A61K38/00 , A61K48/00 , A61P9/10 , A61P35/00 , A61P43/00 , C12N15/113
CPC分类号： C12N15/113 , A61K38/00 , A61K48/00 , C12N2310/111 , C12N2310/14
摘要： PROBLEM TO BE SOLVED: To provide an RNA inhibiting the expression of a Kruppel-like factor 5 (KLF5) gene. SOLUTION: The RNA comprises a sequence of consecutive 15 to 30 bases of KLF5 mRNA designed from the base sequence of KLF5 cDNA and its complimentary sequence, and inhibits the expression of KLF5 gene. In particular, a double stranded RNA having two uridylic acids added to the 3' end of each of the strands of the double stranded RNA composed of a strand of a specific sequence and a strand of a sequence complementary to the above sequence. The expression of KLF5 gene in a cell can be inhibited by the infusion of the RNA or a vector capable of expressing the RNA into the cell. The RNA or the vector capable of expressing the RNA can be used as a curative medicine for cardiovascular diseases or cancers. COPYRIGHT: (C)2006,JPO&NCIPI
摘要翻译：待解决的问题：提供抑制Kruppel样因子5（KLF5）基因表达的RNA。解决方案：RNA包含从KLF5 cDNA的碱基序列及其互补序列设计的KLF5 mRNA的连续15-30个碱基序列，并抑制KLF5基因的表达。特别地，将由特定序列的链和与上述序列互补的序列的链组成的双链RNA的每条链的3'末端加入两个尿苷酸的双链RNA。 KLF5基因在细胞中的表达可以通过将RNA或能够将RNA表达的细胞输入细胞来抑制。能够表达RNA的RNA或载体可用作心血管疾病或癌症的治疗药物。版权所有（C）2006，JPO＆NCIPI

4. 发明专利

JP2005291819A Screening method of remedy component of metabolic syndrome, and diagnostic method of metabolic syndrome 有权
标题翻译：代谢综合征补救成分筛选方法及代谢综合征诊断方法
公开(公告)号：JP2005291819A
公开(公告)日：2005-10-20
申请号：JP2004104923
申请日：2004-03-31
申请人： Ichiro Manabe , Ryozo Nagai , Yumiko Oishi , 由美子大石 , 良三永井 , 一郎眞鍋
发明人： NAGAI RYOZO , MANABE ICHIRO , OISHI YUMIKO
IPC分类号： G01N33/50 , C12N15/09 , C12Q1/66 , C12Q1/68 , G01N33/15 , G01N33/53 , G01N33/566
摘要： PROBLEM TO BE SOLVED: To provide a screening method of a component material of a metabolic syndrome remedy, and a method for diagnosing the metabolic syndrome.
SOLUTION: This screening method of the remedy component of the metabolic syndrome is characterized by adding a test material to a system capable of detecting formation of a KLF5-PRARγ complex by a signal of reporter molecules, and specifying an activity adjusting material of the KLF5-PRARγ complex by using the signal quantity of the reporter molecules as an index. This diagnostic method of the metabolic syndrome is characterized by measuring the KLF5 manifestation quantity in a fat tissue isolated from a subject.
COPYRIGHT: (C)2006,JPO&NCIPI
摘要翻译：待解决的问题：提供代谢综合征治疗的成分材料的筛选方法，以及诊断代谢综合征的方法。解决方案：代谢综合征的补救成分的筛选方法的特征在于，将测试材料加入能够通过报道分子的信号检测KLF5-PRARγ复合物形成的系统，并指定活性调节材料 KLF5-PRARγ复合物通过使用报告分子的信号量作为指标。代谢综合征的这种诊断方法的特征在于测量从受试者分离的脂肪组织中的KLF5表现量。版权所有（C）2006，JPO＆NCIPI

5. 发明申请

US20130210860A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT AGAINST LYMPHEDEMA 审中-公开
标题翻译：丙酸和/或治疗代谢物对抗LYMPHEDEMA
公开(公告)号：US20130210860A1
公开(公告)日：2013-08-15
申请号：US13878136
申请日：2011-10-05
申请人： Ichiro Manabe , Ryozo Nagai , Fusa Ogata
发明人： Ichiro Manabe , Ryozo Nagai , Fusa Ogata
IPC分类号： A61K31/22 , A61K31/40 , A61K31/47
CPC分类号： A61K31/22 , A61K31/366 , A61K31/40 , A61K31/404 , A61K31/44 , A61K31/47 , A61K31/505
摘要： Provided is a new prophylactic and/or therapeutic agent for lymphedema, for which until now there has been no effective means of treatment, and the prophylactic and/or therapeutic agent for lymphedema comprises, as an active ingredient, a compound represented by the following formula (1), a lactone derivative thereof, or a salt of the compound or lactone derivative: wherein R1 represents an organic group, X represents —CH2CH2— or —CH=CH—, and R2 represents a hydrogen atom or an alkyl group.
摘要翻译：提供了一种用于淋巴水肿的新的预防和/或治疗剂，迄今为止没有有效的治疗方法，并且用于淋巴水肿的预防和/或治疗剂包含作为活性成分的由下式表示的化合物（1）表示的化合物或其内酯衍生物或化合物或内酯衍生物的盐：其中R1表示有机基团，X表示-CH2CH2-或-CH = CH-，R2表示氢原子或烷基。

6. 发明申请

US20100120674A1 INSULIN RESISTANCE IMPROVING AGENTS 有权
标题翻译：胰岛素电阻改善剂
公开(公告)号：US20100120674A1
公开(公告)日：2010-05-13
申请号：US12041279
申请日：2008-03-03
申请人： TAKASHI KADOWAKI , TOSHIMASA YAMAUCHI , JUNJI KAMON , HIRONORI WAKI , RYOZO NAGAI , SATOSHI KIMURA , MOTOO TOMITA
发明人： TAKASHI KADOWAKI , TOSHIMASA YAMAUCHI , JUNJI KAMON , HIRONORI WAKI , RYOZO NAGAI , SATOSHI KIMURA , MOTOO TOMITA
IPC分类号： A61K38/22 , A61P3/00
CPC分类号： A61K38/2264
摘要： The invention provides an insulin resistance improving agent and a therapeutic agent for type 2 diabetes, which contain a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention also provides a method for improving insulin resistance and treating type 2 diabetes by administering the aforementioned agent(s).
摘要翻译：本发明提供胰岛素抵抗改善剂和2型糖尿病治疗剂，其含有脂联素的C末端球状结构域，脂联素或结合域或脂联素的基因。本发明还提供了一种通过施用上述药物来改善胰岛素抵抗和治疗2型糖尿病的方法。

7. 发明申请

US20090175930A1 Composition Suppressing The Expression of Target Gene in Eyeball and Medicament For Treating of Disease in Eyeball 审中-公开
标题翻译：抑制眼球中靶基因表达和治疗眼球疾病药物的组合物
公开(公告)号：US20090175930A1
公开(公告)日：2009-07-09
申请号：US12087674
申请日：2007-01-10
申请人： Nobuhiro Yagi , Masahiro Yamauchi , Noboru Aoki , Yasuhiro Tamaki , Hidenori Takahashi , Aya Iriyama , Ryozo Nagai , Ichiro Manabe
发明人： Nobuhiro Yagi , Masahiro Yamauchi , Noboru Aoki , Yasuhiro Tamaki , Hidenori Takahashi , Aya Iriyama , Ryozo Nagai , Ichiro Manabe
IPC分类号： A61K9/127 , A61K31/7052 , A61P27/02
CPC分类号： A61K9/1272 , A61K9/0048 , A61K9/127 , A61K31/7105 , A61K48/0033 , A61K48/0041 , C12N15/111 , C12N2310/14 , C12N2320/32
摘要： There is provided a composition comprising an RNA-encapsulated liposome, the RNA comprising a sequence being of 15 to 30 contiguous nucleotides of mRNA of a target gene associated with a disease in an eyeball, and a sequence complementary to the sequence, wherein the liposome is capable of reaching an eyeball, and the like. The liposome in which an RNA is encapsulated is, for example, a liposome composing a complex particle comprising a lead particle and the RNA as constituent components, the lead particle comprising a cationic lipid, and a bilayer lipid membrane for coating the complex particle. The bilayer lipid membrane is a bilayer lipid membrane comprising a neutral lipid, and a lipid derivative, a fatty acid derivative or an aliphatic hydrocarbon derivative of a water-soluble substance as constituent components.
摘要翻译：提供了包含RNA包封的脂质体的组合物，所述RNA包含与眼球中的疾病相关的靶基因的mRNA的15-30个连续核苷酸的序列和与该序列互补的序列，其中所述脂质体是能够达到眼球等。其中包封RNA的脂质体是例如构成包含铅颗粒和RNA作为组成成分的复合颗粒的脂质体，包含阳离子脂质的铅颗粒和用于涂覆复合颗粒的双层脂质膜。双层脂质膜是包含中性脂质和作为组成成分的水溶性物质的脂质衍生物，脂肪酸衍生物或脂肪族烃衍生物的双层脂质膜。

8. 发明授权

US07501490B2 Adiponectin receptor and gene encoding the same 有权
标题翻译：脂联素受体和基因编码相同
公开(公告)号：US07501490B2
公开(公告)日：2009-03-10
申请号：US11598474
申请日：2006-11-13
申请人： Takashi Kadowaki , Toshimasa Yamauchi , Ryozo Nagai , Junji Kamon
发明人： Takashi Kadowaki , Toshimasa Yamauchi , Ryozo Nagai , Junji Kamon
IPC分类号： C07K1/00 , G01N33/53 , G01N33/566
CPC分类号： C07K14/72 , Y10S435/81
摘要： The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.
摘要翻译：目的是分离和鉴定人和小鼠脂联素受体，以提供具有脂联素结合能力的新型蛋白质，并提供使用这种蛋白质的脂联素受体的配体，激动剂和拮抗剂的筛选方法和筛选试剂盒。为了实现这个目的，使用蛋白质作为具有脂联素结合能力的新型蛋白质，即（a）包含根据Seq的氨基酸序列的蛋白质。 No.2,4,6或8，或（b）包含根据Seq的氨基酸序列的蛋白质。具有一个或多个缺失，替换或添加的氨基酸并具有脂联素结合能力的2,4,6或8号。

9. 发明申请

US20070049579A1 Medicament having neovascularization promoting action 审中-公开
标题翻译：具有新血管形成促进作用的药物
公开(公告)号：US20070049579A1
公开(公告)日：2007-03-01
申请号：US11366454
申请日：2006-03-03
申请人： Ryozo Nagai , Ichiro Manabe , Takayuki Shindo , Hiroshi Iwata , Koichi Shudo , Hiroyuki Kagechika
发明人： Ryozo Nagai , Ichiro Manabe , Takayuki Shindo , Hiroshi Iwata , Koichi Shudo , Hiroyuki Kagechika
IPC分类号： A61K31/551
CPC分类号： A61K31/551
摘要： A medicament having a neovascularization promoting action, which comprises a retinoid antagonist such as 4-(5H-7,8,9,10-tetrahydro-5,7,7,10,10-pentamethylbenzo[e]naphtho[2,3-b][1,4]diazepin-13-yl)benzoic acid as an active ingredient and is useful for prophylactic and/or therapeutic treatment of ischemic diseases and wounds.
摘要翻译：具有新血管形成促进作用的药物，其包含类视黄醇拮抗剂，例如4-（5H-7,8,9,10-四氢-5,7,7,10,10-五甲基苯并[e]萘并[2,3- b] [1,4]二氮杂萘-13-基）苯甲酸作为活性成分，可用于预防和/或治疗缺血性疾病和伤口。

10. 发明申请

US20060199761A1 Insulin resistance improving agent 审中-公开
标题翻译：胰岛素抵抗改善剂
公开(公告)号：US20060199761A1
公开(公告)日：2006-09-07
申请号：US10502051
申请日：2002-07-26
申请人： Takashi Kadowaki , Toshimasa Yamauchi , Junji Kamon , Hironori Waki , Ryozo Nagai , Satoshi Kimura , Motto Tomita
发明人： Takashi Kadowaki , Toshimasa Yamauchi , Junji Kamon , Hironori Waki , Ryozo Nagai , Satoshi Kimura , Motto Tomita
IPC分类号： A61K38/17 , A61K48/00
CPC分类号： A61K38/2264
摘要： The invention provides an insulin resistance improving agent which contains, as an active component, a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention also provides a therapeutic agent for type 2 diabetes, which contains, as an active component, a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention reverses insulin resistance induced from a high fat diet and associated with obesity, and therefore, enables treatment of type 2 diabetes, which is the most common among other types of diabetes.
摘要翻译：本发明提供一种胰岛素抵抗性改善剂，其包含作为活性成分的脂联素的C末端球状结构域，脂联素或所述结构域或脂联素的基因。本发明还提供了用于2型糖尿病的治疗剂，其包含作为活性成分的脂联素的C末端球状结构域，脂联素或所述结构域或脂联素的基因。本发明逆转高脂肪饮食诱发的胰岛素抵抗并与肥胖相关，因此能够治疗其它类型糖尿病中最常见的2型糖尿病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式